Tricor Receives FDA Approval For Very High Triglycerides
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Tricor Receives FDA Approval For Very High Triglycerides

ABBOTT PARK, IL -- February 12, 1998 -- The United States Food and Drug Administration has granted marketing clearance to Abbott Laboratories and Groupe Fournier’s Tricor(TM), a micronized form of the drug fenofibrate, for patients with very high triglyceride levels.

Fenofibrate is sold in 77 countries worldwide under the primary brand names Lipanthyl(R) and Lipidil(R). Abbott will market Tricor in the United States under a 1997 licensing agreement with the drug's developer, Groupe Fournier.

In the U.S., Tricor is indicated as an adjunct to diet for the treatment of adults with very high serum triglyceride levels, specifically Types IV and V hyperlipidemia, who are not appropriately controlled by diet alone and are at risk of pancreatitis. Tricor should not be used in patients with liver, gall bladder or severe kidney disease, or in patients who are allergic to the drug.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities